Introduction People living with human immunodeficiency virus (PLWH) have higher mortality
rates from COVID-19 than those without HIV. Additionally, the seroconversion rate of …

Vaccines have curtailed the devastation wrought by COVID-19. Nevertheless, emerging
variants result in a high incidence of breakthrough infections. Here we assess the impact of …

Background People with human immunodeficiency virus (HIV) on antiretroviral therapy
(ART) with good CD4 T-cell counts make effective immune responses following vaccination …

Background: Limited data are available on the long-term clinical and immunologic
consequences of SARS-CoV-2 infection in people with HIV (PWH). Methods: We measured …

Introduction People living with HIV (PLWH) are at a higher risk of severe disease with SARS-
CoV-2 virus infection. COVID-19 vaccines are effective in most PLWH. However, suboptimal …

Background: To analyze the efficacy and safety of SARS-CoV-2 inactivated vaccine in
people living with HIV (PLWH). Methods: A total of 143 PLWH were included in the study. All …

Abstract Purpose of Review In this review, we examine the intersection of the HIV and
COVID-19 epidemics with focus on COVID-19-related health outcomes and risk factors for …

Background: Longer-term humoral responses to two-dose COVID-19 vaccines remain
incompletely characterized in people living with HIV (PLWH), as do initial responses to a …

Objectives People living with HIV (PLWH) with low CD4 T‐cell counts may be at a higher risk
for severe coronavirus disease 2019 (COVID‐19) outcomes and in need of efficient …

Background Currently, data on long-term immune responses to a homogenous booster dose
of the inactivated COVID-19 vaccine are still limited among people living with HIV (PLWH) …